Literature DB >> 27412420

Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.

Michiya Nishino1, Mai P Hoang2, Patricia Della Pelle2, Vicente Morales-Oyarvide2, Tiffany G Huynh2, Eugene J Mark2, Mari Mino-Kenudson2.   

Abstract

BACKGROUND: Subtyping non-small cell lung carcinomas (NSCLC) into adenocarcinoma (ACA) or squamous cell carcinoma (SQCC) is important for treatment and specimen triage for molecular studies. To preserve tissue for molecular studies in cytology/small biopsy specimens, a 2-antibody cocktail for NSCLC subtyping was developed.
METHODS: Markers for lung ACA (thyroid transcription factor 1 and napsin A) and SQCC (cytokeratin 5/6 and p40) were evaluated on tissue microarrays (TMAs) with 143 ACA and 98 SQCC specimens. The napsin A/p40 combination was selected for NSCLC subtyping and validated on the TMA as well as on a cohort of cell block/small biopsy specimens from 80 poorly differentiated NSCLCs.
RESULTS: Using TMA analysis, the napsin A-positive (+)/p40± immunophenotype identified ACA with 94% sensitivity and 100% specificity, whereas the napsin A (negative)-/p40+ immunophenotype identified SQCC with 100% sensitivity and specificity. On the validation cohort of 80 cell block and small biopsy specimens, the napsin A/p40 cocktail accurately subtyped 63 of 70 NSCLC (90%) as ACA or SQCC using the subsequent surgical resection as reference histology. Of the remaining 17 cases, 15 were classified as NSCLC-not otherwise specified based on a napsin A-/p40- immunophenotype; their corresponding resections were diagnosed as ACA (7 cases), large cell carcinoma (7 cases), or pleomorphic carcinoma (1 case). Two additional large cell carcinoma cases showed a napsin A-/p40+ or napsin A+/p40+ profile in the preoperative cell block/small biopsy sample.
CONCLUSIONS: A napsin A/p40 cocktail can accurately subtype NSCLC into ACA and SQCC in most cell block/small biopsy specimens of poorly differentiated NSCLC. In the minority of cases in which the napsin A/p40 immunophenotype is indeterminate, additional stains may be necessary for precise classification. Cancer Cytopathol 2016;124:472-84.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  adenocarcinoma; cytology; napsin A; non-small cell lung cancer; p40 (ΔNp63); small biopsy; squamous cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27412420     DOI: 10.1002/cncy.21707

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  5 in total

1.  S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells.

Authors:  Rui Wang; Yunguang Li; Enze Hu; Fei Kong; Junhao Wang; Jin Liu; Qirui Shao; Ying Hao; Dacheng He; Xueyuan Xiao
Journal:  Oncotarget       Date:  2017-04-11

2.  Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics.

Authors:  Kajsa Ericson Lindquist; Inga Gudinaviciene; Nektaria Mylona; Rodrigo Urdar; Maria Lianou; Eva Darai-Ramqvist; Felix Haglund; Mátyás Béndek; Erika Bardoczi; Katalin Dobra; Hans Brunnström
Journal:  Biomolecules       Date:  2021-11-18

3.  Portrait of Tissue-Specific Coexpression Networks of Noncoding RNAs (miRNA and lncRNA) and mRNAs in Normal Tissues.

Authors:  Claudia Cava; Gloria Bertoli; Isabella Castiglioni
Journal:  Comput Math Methods Med       Date:  2019-09-03       Impact factor: 2.238

4.  Use of dual-marker staining to differentiate between lung squamous cell carcinoma and adenocarcinoma.

Authors:  Rui Guo; Yi Tian; Na Zhang; Hong Huang; Ying Huang; Jun Yang
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

5.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.